{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T12:20:24Z","timestamp":1776082824216,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003197","name":"Agenzia Italiana del Farmaco, Ministero della Salute","doi-asserted-by":"publisher","award":["FARM12JCXN"],"award-info":[{"award-number":["FARM12JCXN"]}],"id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003866","name":"John Tracy Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003866","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.ijcard.2019.06.055","type":"journal-article","created":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T11:48:29Z","timestamp":1561031309000},"page":"141-147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Primary aldosteronism-associated cardiomyopathy: Clinical-pathologic impact of aldosterone normalization"],"prefix":"10.1016","volume":"292","author":[{"given":"Andrea","family":"Frustaci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Letizia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romina","family":"Verardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Grande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Francone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Sansone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo Antonio","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Chimenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2019.06.055_bb0005","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1161\/01.CIR.92.2.175","article-title":"Pre-requisite for cardiac aldosterone action. Mineralocorticoid receptor and 11-beta-hydroxysteroid dehydrogenase in the human heart","volume":"92","author":"Lomb\u00e8s","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2019.06.055_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18051032","article-title":"Aldosterone and mineralocorticoid receptors. Physiology and pathophysiology","volume":"18","author":"Funder","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijcard.2019.06.055_bb0015","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.116.004815","article-title":"Cardiac remodeling in patients with primary and secondary aldosteronism. A tissue Doppler study","volume":"9","author":"Cesari","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.ijcard.2019.06.055_bb0020","doi-asserted-by":"crossref","first-page":"5070","DOI":"10.1210\/jc.2005-0681","article-title":"Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I","volume":"90","author":"Stowasser","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ijcard.2019.06.055_bb0025","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Emme","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2019.06.055_bb0030","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"A selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2019.06.055_bb0035","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.108.778811","article-title":"Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction and Heart Failure Efficacy and Survival Study (EPHESUS)","volume":"118","author":"Pitt","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2019.06.055_bb0040","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2019.06.055_bb0045","first-page":"1","article-title":"2013 ACCF\/AHA guideline for the management of heart failure","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2019.06.055_bb0050","first-page":"1","article-title":"2016 ACC\/AHA\/HFSA update on new pharmacological therapy for heart failure: an update of the 2013 ACCF\/AHA guideline for the management of heart failure","volume":"134","author":"Yancy","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2019.06.055_bb0055","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/ejhf.796","article-title":"Myocardial expression of Toll-like receptor 4 predicts the response to immunosuppressive therapy in patients with virus-negative chronic inflammatory cardiomyopathy","volume":"19","author":"Chimenti","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2019.06.055_bb0060","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1161\/01.RES.71.3.503","article-title":"Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor","volume":"71","author":"Lomb\u00e8s","year":"1992","journal-title":"Circ. Res."},{"key":"10.1016\/j.ijcard.2019.06.055_bb0065","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","article-title":"Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism","volume":"45","author":"Milliez","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"issue":"Suppl. 1","key":"10.1016\/j.ijcard.2019.06.055_bb0070","first-page":"107","article-title":"Myocardial fibrosis: role of angiotensin II and aldosterone","volume":"88","author":"Weber","year":"1993","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.ijcard.2019.06.055_bb0075","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00395-013-0393-6","article-title":"Cardiac aquaporins","volume":"108","author":"Rutkovskiy","year":"2013","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.ijcard.2019.06.055_bb0080","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/487256","article-title":"Ouabain-induced cytoplasmic vesicles and their role in cell volume maintenance","volume":"2015","author":"Russo","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.ijcard.2019.06.055_bb0085","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10877","article-title":"Myocardial pathology induced by aldosterone is dependent on non-canonical activities of G protein-coupled receptor kinases","volume":"7","author":"Cannavo","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijcard.2019.06.055_bb0090","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1161\/01.HYP.0000123573.60340.9b","article-title":"The many targets of aldosterone","volume":"43","author":"Schiffrin","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2019.06.055_bb0095","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/01.HYP.28.5.785","article-title":"Vascular hypertrophy and remodeling in secondary hypertension","volume":"28","author":"Rizzoni","year":"1996","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.ijcard.2019.06.055_bb0100","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s000590050024","article-title":"Aldosterone and myocardial fibrosis in heart failure","author":"Brilla","year":"2000","journal-title":"Herz"},{"key":"10.1016\/j.ijcard.2019.06.055_bb0105","first-page":"I","article-title":"Aldosterone-induced expression of ET1, ET3 and ETB receptors by cultured adult rat cardiac fibroblasts","volume":"94","author":"Katwa","year":"1996","journal-title":"Circulation"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527319316328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527319316328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T20:05:43Z","timestamp":1734638743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527319316328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":21,"alternative-id":["S0167527319316328"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2019.06.055","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary aldosteronism-associated cardiomyopathy: Clinical-pathologic impact of aldosterone normalization","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2019.06.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}